RxDoctor Payments Data

Sandra Spackman, APRN

Acute Care · Tooele, UTNPI 1164892592

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 26 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 10 manufacturers reported payments, led by Novartis at 57.7% of the total.

$463in general payments, 2019–2025

Across 26 payments — averaging $17.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$268
  • Pfizer$35
  • Azurity Pharmaceuticals, Inc.$31
  • Heartflow, Inc.$26
  • Abbott$24
  • Amgen$18
  • plus $62 from 4 others

What the payments were for

  • Food & beverage$463100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$463 in reported general payments places this provider in the 65th percentile of 119 acute care providers in Utah.

See all acute care providers in Utah

Medicare billing

Part B allowed, 2024
$61,854
Medicare patients
315
Services billed
833

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban38$61,776
EntrestoSacubitril/Valsartan46$51,401
XareltoRivaroxaban41$48,078
JardianceEmpagliflozin43$44,673
FarxigaDapagliflozin Propanediol37$43,586
Repatha SureclickEvolocumab47$34,309
Praluent PenAlirocumab17$13,542
Rosuvastatin Calcium396$4,917
Metoprolol Succinate307$3,419
Atorvastatin Calcium211$2,225
Ezetimibe95$1,879
Spironolactone203$1,827
Nadolol13$1,216
Nitroglycerin132$1,202
Losartan Potassium124$1,132

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$35$61,77638 claims
NovartisEntresto$268$51,40146 claims
AstraZenecaFarxiga$18$43,58637 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 119 acute care providers in Utah.

Other acute care in Tooele

See the full list for Utah

Where these figures come from

Is this you, or does something look wrong? →